EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Prognostic impact of residual viable tumor percentage on non-small cell lung cancer recurrence after neoadjuvant immunochemotherapy

Ruihe Liu, Shenhua Liang, Jiayuan Tian, Yitao Yang, Xingyu Luo, Guowei Ma

Cancer Treatment and Research Communications · 2026 · 49 · 101462

DOI: 10.1016/j.ctarc.2026.101462 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Ruihe Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation C…. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Recent clinical trials have identified the percentage of residual viable tumor (%RVT) following neoadjuvant immunochemotherapy as a prognostic risk factor for patients with non-small cell lung cancer (NSCLC). This study aimed to identify the significance of %RVT concerning the patterns of postoperative recurrence. METHODS: This retrospective study involved 339 patients diagnosed with NSCLC who underwent neoadjuvant immunochemotherapy followed by radical surgical intervention. The optimal cutoff value of %RVT was identified as a continuous covariate for recurrence-free survival (RFS) using the rolr R package. RESULTS: In our cohort, the estimated optimal cutoffs for %RVT were identified as 5% and 30%. Patients with >30% RVT exhibited significantly worse RFS compared to those with 6-30% RVT (P = 0.026) and those with ≤5% RVT (P 30% RVT, 37.1%; P 30% RVT, 24.7%; P < 0.001) increased progressively with advancing %RVT. Cox regression analyses revealed that %RVT, visceral pleural infiltration, lymphovascular infiltration, and pN stage were independent risk factors for RFS. Based on these identified factors, a nomogram model was subsequently developed, yielding a corrected C-index of 0.701 through bootstrap analysis. CONCLUSIONS: We identified %RVT in post-treatment tumor lesions as a significant risk factor for the recurrence of NSCLC following neoadjuvant immunochemotherapy and surgery, with optimal cutoffs established at 5% and 30%. Furthermore, an increase in %RVT may have a more pronounced effect on distant recurrence.

Schlagwörter

Stichwörter der Autor:innen

Neoadjuvant immunochemotherapyPercentage of residual viable tumorReal-world studyRecurrence-free survival

Autor:innen und Institutionen

  • The Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • The Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. Electronic address: magw@…

Zitieren

APA

Liu, R., Liang, S., Tian, J., Yang, Y., Luo, X., & Ma, G. (2026). Prognostic impact of residual viable tumor percentage on non-small cell lung cancer recurrence after neoadjuvant immunochemotherapy. Cancer Treatment and Research Communications, 49, 101462. https://doi.org/10.1016/j.ctarc.2026.101462

Vancouver

Liu R, Liang S, Tian J, Yang Y, Luo X, Ma G. Prognostic impact of residual viable tumor percentage on non-small cell lung cancer recurrence after neoadjuvant immunochemotherapy. Cancer Treatment and Research Communications. 2026;49:101462. doi:10.1016/j.ctarc.2026.101462

BibTeX
@article{Liu2026,
  author = {Liu, Ruihe and Liang, Shenhua and Tian, Jiayuan and Yang, Yitao and Luo, Xingyu and Ma, Guowei},
  title = {Prognostic impact of residual viable tumor percentage on non-small cell lung cancer recurrence after neoadjuvant immunochemotherapy},
  journal = {Cancer Treatment and Research Communications},
  year = {2026},
  volume = {49},
  pages = {101462},
  doi = {10.1016/j.ctarc.2026.101462}
}
Kostenlos starten →